$PTLA Headlines Results from study of Portola's

$PTLA Headlines

Results from study of Portola's factor Xa inhibitor antidote presented at ASH 11:27 a.m. Dec. 9, 2013 - Seeking Alpha
Portola Pharma Reports New Phase 2 Results Confirming Immediate, Dose-Dependent, Well-Tolerated Reversal of Anticoagulation Activity of XARELTO 10:05 a.m. Dec. 9, 2013 - benzinga.com
ASH Conference: 3 Companies To Watch 10:53 a.m. Dec. 8, 2013 - Seeking Alpha
A Chart You Should See: Biotech IPO Class of 2013 Is Lagging 9:42 a.m. Nov. 26, 2013 - TheStreet.com
Health-Care Stocks: Where to Find Value 6:08 a.m. Nov. 12, 2013 - Barrons.com
Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*) 7:03 a.m. Nov. 11, 2013 - benzinga.com
10-Q: PORTOLA PHARMACEUTICALS INC 5:26 p.m. Nov. 6, 2013 - Edgar Online - (EDG = 10Q, 10K)
Portola Pharmaceuticals Inc's CEO Discusses Q3 2013 Results - Earnings Call Transcript 12:23 a.m. Nov. 6, 2013 - Seeking Alpha
Portola Pharmaceuticals: A Biotech Company With Plenty Of Room To Grow 12:18 p.m. Oct. 30, 2013 - Seeking Alpha
Portola Strengthens On Hopes For Cardiovascular Franchise 1:46 p.m. Oct. 21, 2013 - Seeking Alpha
Portola Prices Public Offering - Analyst Blog 4:30 p.m. Oct. 18, 2013 - Zacks.com
Data on Portola's Andexanet Alfa - Analyst Blog 4:30 p.m. Oct. 15, 2013 - Zacks.com
Portola Pharma Issues Results for First Phase 2 Trial Showing Extended Duration Infusion with PRT4445 3:06 p.m. Oct. 14, 2013 - benzinga.com
Update on Portola's Pipeline - Analyst Blog 12:40 p.m. Oct. 14, 2013 - Zacks.com
Portola Pharmaceuticals to Present Preclinical Data on Andexanet Alfa 6:05 a.m. Aug. 29, 2013 - benzinga.com
Portola Pharmaceuticals' CEO Discusses 2Q 2013 Results - Earnings Call Transcript 1:44 p.m. Aug. 16, 2013 - Seeking Alpha
Encouraging Data on Portola's PRT4445 - Analyst Blog 4:20 p.m. July 9, 2013 - Zacks.com
Bayer Announces Positive Phase I Data - Analyst Blog 4:00 p.m. July 8, 2013 - Zacks.com
Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R) 5:32 a.m. July 2, 2013 - benzinga.com
Portola Pharmaceuticals: Developing The Novel Therapies In Blood Clot Formation Disorders 3:01 p.m. July 1, 2013 - Seeking Alpha


Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban) With Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Reversal Agent 11:00 a.m. Dec. 9, 2013 - GlobeNewswire
District Court Ruling, Cash Tender Offers, Celebration Events, Conference Presentations, and Repurchase Programs - Research Report on AstraZeneca, Salix, Health Net, Volcano and Portola 8:00 a.m. Dec. 9, 2013 - PR Newswire
Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa (PRT4445*) and PRT2070 at 55th American Society of Hematology (ASH) Annual Meeting 8:00 a.m. Dec. 3, 2013 - GlobeNewswire
Proposed M&A's, Conference Schedules, Health Awareness Programs, Prestigious Recognitions and FDA Designations - Research Report on Health Management, Acadia, Health Net, NuVasive and Portola 8:00 a.m. Nov. 29, 2013 - PR Newswire
Portola Pharmaceuticals Receives Breakthrough Therapy Designation From FDA for Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Antidote 8:01 a.m. Nov. 25, 2013 - GlobeNewswire
Disaster Relief Contributions, New Medical Trials, Clinical Results and Employee Incentives - Research Report on UnitedHealth Group, ACADIA, USANA, Portola and Horizon Pharma 8:00 a.m. Nov. 21, 2013 - PR Newswire
Solid Growth Derived from Successful Product Launches and Registrations - Research Report on Volcano, Dr. Reddy's, USANA, Repligen, and Portola 8:11 a.m. Nov. 13, 2013 - PR Newswire
Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*) 8:01 a.m. Nov. 11, 2013 - GlobeNewswire
Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update 4:00 p.m. Nov. 5, 2013 - GlobeNewswire
Portola Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013 7:00 a.m. Oct. 31, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Genetically-Defined Hematologic Cancers 3:00 p.m. Oct. 24, 2013 - GlobeNewswire
Divestiture, Clinical Study Updates, New Drug Application, and Quarterly Report - Research Report on Geron, NPS, Portola, MannKind, and Exact Sciences 7:00 a.m. Oct. 21, 2013 - PR Newswire
PACT, EBAY, AMRN and PTLA added to NASDAQ Active Stock Watch List at GSR 9:10 a.m. Oct. 17, 2013 - ACCESSWIRE
Portola Announces Pricing of Public Offering of Common Stock 7:33 a.m. Oct. 17, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Proposed Offering of Common Stock 5:56 a.m. Oct. 16, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Release of Lock-up Restriction for Common Stock Held by a Director of the Company 4:05 p.m. Oct. 15, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445*) Provides Prolonged Reversal of Anticoagulation Activity of Factor Xa Inhibitor Eliquis(R) 4:05 p.m. Oct. 14, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of PRT2070 7:01 a.m. Oct. 9, 2013 - GlobeNewswire
Vital Therapies, Inc. Expands Board of Directors 5:01 a.m. Sept. 20, 2013 - Marketwire
Portola Pharmaceuticals Announces Participation at Upcoming Investor Conferences 7:01 a.m. Sept. 5, 2013 - GlobeNewswire